Health Trials

Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial

ConditionPost-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age20+
SponsorNational Taiwan University Hospital

About this trial

Post-operative atrial fibrillation after coronary artery bypass grafting (CABG)

Eligibility criteria

Qualifiers

Adults aged 20 years or older scheduled to undergo elective coronary artery bypass grafting (CABG), including either off-pump CABG or on-pump CABG.

Ability to receive oral study medication before and after surgery.

Provision of written informed consent before randomization.

Disqualifiers

History of atrial fibrillation or atrial flutter before surgery.

Severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m²) or chronic dialysis.

Severe hepatic dysfunction.

Known hypersensitivity or previous severe adverse reaction to colchicine.

Trial design

Treatments tested in this trial

  • Colchicine 0.5 MG oral tablet twice daily
  • Placebo Oral Tablet

Treatment groups

400 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

National Taiwan University Hospital

Lead sponsor

Source ClinicalTrials.gov